Tiziana Life Sciences PLC (NASDAQ:TLSA)'s CEO Dr. Kunwar Shailubhai tells Proactive a second patient with Secondary Progressive Multiple Sclerosis (SPMS) in an ongoing study has shown clinical improvements following three months of treatment with its intranasal drug foralumab. The patient showed improvements based on Positron Emission Tomography (PET) imaging analysis, a neurologic exam and a timed 25-foot walk test. These findings are consistent with the results obtained from the first patient following three months of treatment, as previously announced in March.
Tiziana Life Sciences welcomes positive results from second patient in Foralumab MS study
